TrialEye (London, England)2012

Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.

D M Paskowitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.